# US 2011/0256623 A1 · Primate Embryonic Stem Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0256623 A1
- Document ID: US20110256623A1
- Status: Published application
- Kind: A1
- Application number: 12/822,004
- Filed: 2010-06-23
- Published: 2011-10-20
- Earliest claimed: 1995-01-20
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: JAMES A. THOMSON
- Web page: https://patentgrep.com/patent/US20110256623A1

## CPC

- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/16: Anti-Parkinson drugs
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 2502/13: connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed.

## Claims

### Claim at position 1

-11. (canceled)

### Claim 12

A preparation of pluripotent human stem cells comprising cells that (i) proliferate in vitro for over one year, (ii) maintain a karyotype in which the chromosomes are euploid through prolonged culture, (iii) maintain the potential to differentiate to derivatives of endoderm, mesoderm, and ectoderm tissues, (iv) are inhibited from differentiation when cultured on a fibroblast feeder layer, and (v) are negative for the SSEA-1 cell surface marker and positive for SSEA-4 cell surface marker.

### Claim 13 (depends on 12)

The preparation of claim 12, wherein the stem cells will spontaneously differentiate to trophoblasts that produce chorionic gonadotropin when cultured beyond confluence.

### Claim 14 (depends on 12)

The preparation of pluripotent human stem cells as claimed in claim 12 wherein the cells express alkaline phosphatase activity.

### Claim 15 (depends on 14)

The preparation of claim 14, wherein the cells are positive for the TRA-1-60, and TRA-1-81 markers.

### Claim 16 (depends on 13)

The preparation of claim 13, wherein the cells will differentiate to trophoblasts that produce chorionic gonadotropin when cultured for two weeks beyond confluence.

### Claim 17 (depends on 14)

The preparation of claim 14, wherein the cells remain euploid for more than one year of continuous culture.

### Claim 18 (depends on 14)

The preparation of claim 14, wherein the cells differentiate into cells derived from mesoderm, endoderm and ectoderm germ layers when the cells are injected into a SCID mouse.
